Fig. 2: Splenic response.
From: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

a, Percentage change in spleen volume from baseline at week 24, overlaid with the proportion of patients with spleen response (defined as a ≥35% reduction in spleen volume from baseline, by central read). Patients without week 24 change from baseline assessment are not shown and were considered nonresponders for spleen response. Difference between treatment arms was compared by stratified Cochran–Mantel–Haenszel test (performed two-sided Cochran–Mantel–Haenszel test at the alpha level 5%). The exact P value is 1.64 × 10−10. b, Kaplan–Meier time-to-event estimate for spleen response.